Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Drops By 12.5%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 7,000 shares, a decline of 12.5% from the November 15th total of 8,000 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 18,600 shares, the short-interest ratio is presently 0.4 days.

Analyst Ratings Changes

Separately, HC Wainwright dropped their target price on shares of Cocrystal Pharma from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, August 22nd.

Cocrystal Pharma Stock Up 5.9 %

COCP stock traded up $0.11 during midday trading on Monday, reaching $2.02. The company had a trading volume of 27,529 shares, compared to its average volume of 20,843. The firm has a market capitalization of $20.55 million, a PE ratio of -1.12 and a beta of 1.52. The stock has a 50 day moving average price of $1.94 and a 200 day moving average price of $2.02. Cocrystal Pharma has a fifty-two week low of $1.33 and a fifty-two week high of $3.10.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.